Australia markets open in 32 minutes

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
51.600.00 (0.00%)
At close: 10:25AM EST

Recordati Industria Chimica e Farmaceutica S.p.A.

Via Matteo Civitali,1
Milan, MI 20148
39 02 487871

IndustryDrug Manufacturers - General
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Robert Koremans M.D.CEO & Director1.96MN/A1962
Mr. Luigi Felice La CorteGroup CFO & Executive Director1.03MN/A1969
Ms. Cathrin PettyExecutive DirectorN/AN/A1973
Mr. Giampiero MazzaExecutive DirectorN/AN/A1969
Mr. Giorgio De PalmaExecutive DirectorN/AN/A1974
Ms. Bibianne BonGroup Chief Legal OfficerN/AN/AN/A
Ms. Laura ContiGroup Communications DirectorN/AN/AN/A
Mr. Gabriele FinziExecutive VP of Corporate Development, Licensing & InnovationN/AN/AN/A
Mr. Roberto TeruzziExecutive Vice President of Group Industrial OperationsN/AN/AN/A
Mr. Raffaele SabiaChief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Corporate governance

Recordati Industria Chimica e Farmaceutica S.p.A.’s ISS governance QualityScore as of 1 March 2024 is 3. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 3; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.